TMDX:NSD-TransMedics Group Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 137.53

Change

+0.56 (+0.41)%

Market Cap

USD 4.36B

Volume

0.67M

Analyst Target

USD 21.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 46.05B
ALGN Align Technology Inc

N/A

USD 19.27B
PODD Insulet Corporation

N/A

USD 13.41B
SWAV Shockwave Medical Inc

N/A

USD 12.57B
BRKR Bruker Corporation

N/A

USD 9.79B
MASI Masimo Corporation

N/A

USD 6.66B
PRCT Procept Biorobotics Corp

N/A

USD 3.54B
AXNX Axonics Modulation Technologie..

N/A

USD 3.43B
TNDM Tandem Diabetes Care Inc

N/A

USD 3.20B
IRTC iRhythm Technologies Inc

N/A

USD 3.02B

ETFs Containing TMDX

CIB0:XETRA VanEck Bionic Engineering.. 3.81 % 0.00 %

N/A

USD 6.31M
XHE SPDR® S&P Health Care Eq.. 2.63 % 0.35 %

N/A

USD 0.26B
MMSC First Trust Multi-Manager.. 1.33 % 0.00 %

N/A

USD 0.02B
QQQS Invesco NASDAQ Future Gen.. 0.89 % 0.00 %

N/A

USD 8.10M
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

N/A

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 74.24% 91% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.24% 91% A- 94% A
Trailing 12 Months  
Capital Gain 92.81% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 92.81% 93% A 94% A
Trailing 5 Years  
Capital Gain 376.21% 97% N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 376.21% 97% N/A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 62.17% 91% A- 92% A
Dividend Return 62.17% 91% A- 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 94.27% 33% F 17% F
Risk Adjusted Return 65.95% 96% N/A 88% B+
Market Capitalization 4.36B 95% A 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.